id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-265812-1hcp36cw	De Jong, Cornelis N.	Etanercept for steroid-refractory acute graft-versus-host disease: A single center experience	2017-10-26		.txt	text/plain	3168	186	53	W.; Van der Klift, Marjolein; Cornelissen, Jan J.; Broers, Annoek E. High dose glucocorticosteroids, are currently recommended as first-line treatment for grade II-IV aGVHD resulting in overall complete responses (CR) in 40%-50% of patients. CONCLUSION: Second-line treatment with etanercept does induce responses in SR-aGVHD of the gut but appears to be associated with poor long-term survival even in responding patients. High dose systemic glucocorticosteroids (steroids) are currently recommended as first-line treatment for grade II-IV aGVHD resulting in overall complete responses (CR) in 40%-50% of patients [2, 3] . Studies evaluating second-line treatment with the anti-TFNα agent etanercept have shown promising results with overall response rates of 50-80% [8] [9] [10] . In conclusion, although second-line treatment of SR-aGVHD of the gut with etanercept was associated with a promising initial response rate, overall survival appeared very poor, mainly due to progression of GVHD and opportunistic infections.	./cache/cord-265812-1hcp36cw.txt	./txt/cord-265812-1hcp36cw.txt